BC
SRPT icon

Bayforest Capital’s Sarepta Therapeutics SRPT Stock Holding History

Bayforest Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Buy
9,962
+2,841
+40% +$53.7K 0.17% 207
2026
Q1 		$155K Buy
+7,121
New +$138K 0.17% 210
2025
Q4 		– Sell
-9,674
Closed -$186K – 954
2025
Q3 		$186K Buy
+9,674
New +$172K 0.09% 401

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bayforest Capital's SRPT Position: Q2 2026 in Review

Bayforest Capital increased its Sarepta Therapeutics (SRPT) stake by 40% in Q2 2026, buying an estimated $53.7K and bringing the position to 9,962 shares worth $179K. The position accounts for 0.17% of the portfolio, ranked #207.

Bayforest Capital first reported a position in SRPT in Q3 2025 and has held it in 3 quarters since. The position peaked at $186K in Q3 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Bayforest Capital held 9,962 shares of Sarepta Therapeutics worth $179K as of Q2 2026.
  • Bayforest Capital bought 2,841 Sarepta Therapeutics shares in Q2 2026, an estimated $53.7K.
  • Sarepta Therapeutics made up 0.17% of Bayforest Capital's portfolio in Q2 2026, its #207 holding.
  • Bayforest Capital first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Bayforest Capital's Sarepta Therapeutics position peaked at $186K in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.